Bio-Rad Laboratories, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Norman D. Schwartz
- Full Time Employees
- 7,700
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1000 Alfred Nobel Drive Hercules CA United States of America 94547
- IPO Date
- Feb 27, 1980
- CIK
- 0000012208
- Website
- bio-rad.com
- Similar Companies
- Business
- Bio-Rad Laboratories, Inc. is a global leader in the development and manufacture of life science research and clinical diagnostics products. Founded in 1952 and headquartered in Hercules, California, the company operates internationally across the United States, Europe, Asia, Canada, and Latin America. Bio-Rad's core products span life science research instruments and consumables, including chromatography resins and media, flow cytometry antibodies, Droplet Digital PCR (ddPCR) platforms and reagents, as well as advanced digital PCR solutions designed for genomic research and applied sciences. In clinical diagnostics, Bio-Rad offers systems and assays for autoimmune testing, infectious disease detection, diabetes monitoring, blood typing and screening, cardiac assessment controls, molecular quality controls, veterinary diagnostics, and water quality testing. The company serves a broad range of customers from research institutions to clinical, hospital, and veterinary laboratories. Recent major changes include the acquisition of Stilla Technologies in the second quarter of 2025, which enhances Bio-Rad's digital PCR portfolio by integrating Stilla’s QX700 series instruments with Bio-Rad's existing QX Continuum system, thereby accelerating innovation in molecular diagnostics and precision medicine. In 2024, Bio-Rad also completed the acquisition of Saber Bio, a company focused on droplet technology for antibody discovery, aligning with its expansion in cell biology products. Additionally, Bio-Rad has launched new products such as the StarBright dyes for flow cytometry to improve multiplexing capabilities and kits for precise mutation detection in oncology applications leveraging its ddPCR technology. These developments support the company’s strategic focus on enhancing automation, throughput, and the sensitivity of its diagnostics platforms, further positioning it as a key player in advancing life science research and clinical diagnostic solutions. Bio-Rad continues to invest in transformative technologies such as Droplet Digital PCR for non-invasive cancer screening and gene therapy production, supported by ongoing product development and expansion of its assay portfolio. The company’s broad product offering includes instruments, software, reagents, and specialized consumables designed to support applications in cell biology, gene expression, protein purification, drug discovery, infectious diseases, and transfusion medicine. With a commitment to innovation and global healthcare advancement, Bio-Rad maintains a strong presence in both the life sciences and clinical diagnostics markets, driving growth through strategic acquisitions, product launches, and enhanced service offerings.
BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN.
BIO-key's RedChip Future Tech Investor Conference Presentation to be Webcast Wed. June 10 at 3pm ET
Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
UPDATE: BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union
BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit UnionBynum, AL
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF Value $318.25 vs Price $318.22
Elliott Targets Bio-Rad After 70% Stock Collapse
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
BIO-key Q1 Bottom-Line Improves on 34% Rise in Revenue; Expects Q2 Profitability on 65% Revenue Increase; Investor Call Today at 10am ET
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
BIO-key Shares Expected to Temporarily Move to OTC™ Markets Tomorrow, Wednesday May 13th Following Nasdaq Suspension After Today's Market Close; BIO-key is Seeking to Restore Nasdaq Listing Expeditiously
Biometric Identity and Authentication Provider BIO-key to host Q1'26 Investor Webcast Monday, May 18th at 10am ET
Bio-Rad to Participate in Upcoming Investor Conferences
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION